echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sanofi clopidogrel aspirin tablets approved in China

    Sanofi clopidogrel aspirin tablets approved in China

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text|Pharmaceutical Mission Hills

    Today, China’s National Food and Drug Administration (NMPA) announced that Sanofi’s application for the listing of the 5.


    Screenshot source: NMPA official website

    From the point of view of the mechanism of action, aspirin is an inhibitor of cyclooxygenase in the process of arachidonic acid metabolism, which can inhibit the synthesis of TXA2.


    Studies have shown that aspirin combined with clopidogrel has a significant therapeutic effect on patients with acute cerebral infarction.


    According to the "Chinese Expert Consensus on Clopidogrel/Aspirin Monolithic Compound Antiplatelet Therapy" initiated and formulated by the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association in 2021, the results of multiple clinical studies show that clopidogrel/aspirin monolithic compound preparations Its antiplatelet effect is not inferior to single-agent combination therapy, and its tolerance is equivalent


    According to the consensus, in addition to efficacy, the special process of clopidogrel/aspirin single-tablet compound preparation can also reduce adverse reactions


    According to statistics, the prevalence and mortality of cardiovascular diseases in China are still on the rise


    According to Sanofi's public information, the development of a single-tablet compound preparation of clopidogrel/aspirin simplifies the treatment plan


    Reference materials:

    [1] On October 11, 2021, the drug approval document pending information is released.


    [3] Li Biyan, Song Zulan, Chen Yu.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.